
Adaptive Biotechnologies Investor Relations Material
Latest events

Q1 2025
Adaptive Biotechnologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Adaptive Biotechnologies Corporation
Access all reports
Adaptive Biotechnologies Corporation operates as a commercial-stage biotechnology company. It provides immunosequencing and immunodiagnostic solutions. Furthermore the company offers research and development, and customer-focused services primarily to academic, government, pharmaceutical, biotechnology, hospital/clinical laboratories, and other companies in the United States and internationally. It operates in two segments, Adaptive Diagnostics and Adaptive Therapeutics. The company's immune system platform analyzes and interprets T cell and B cell receptor sequencing data.
Key slides for Adaptive Biotechnologies Corporation


Q4 2024
Adaptive Biotechnologies Corporation


43rd Annual J.P. Morgan Healthcare Conference 2025
Adaptive Biotechnologies Corporation
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
ADPT
Country
🇺🇸 United States